Lucatumumab
Lucatumumab (pronounced loo-kah-too-moo-mab) is a monoclonal antibody designed for the treatment of cancer. It was developed by Novartis, a Swiss multinational pharmaceutical company.
Etymology
The name "Lucatumumab" is derived from the Latin word "lucatus", meaning "illuminated", and "mumab", a suffix used in the International Nonproprietary Names (INN) for human monoclonal antibodies.
Mechanism of Action
Lucatumumab works by binding to a specific protein called CD40, which is found on the surface of many types of cancer cells. This binding triggers an immune response that can destroy the cancer cells.
Clinical Trials
Lucatumumab has been tested in several clinical trials for various types of cancer, including non-Hodgkin lymphoma and multiple myeloma. However, as of 2021, it has not yet been approved for use by any health regulatory authority.
Related Terms
See Also
External links
- Medical encyclopedia article on Lucatumumab
- Wikipedia's article - Lucatumumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski